| Literature DB >> 22013125 |
Emily W Y Tam1, Vann Chau, Donna M Ferriero, A James Barkovich, Kenneth J Poskitt, Colin Studholme, Eric D-Y Fok, Ruth E Grunau, David V Glidden, Steven P Miller.
Abstract
As survival rates of preterm newborns improve as a result of better medical management, these children increasingly show impaired cognition. These adverse cognitive outcomes are associated with decreases in the volume of the cerebellum. Because animals exhibit reduced preterm cerebellar growth after perinatal exposure to glucocorticoids, we sought to determine whether glucocorticoid exposure and other modifiable factors increased the risk for these adverse outcomes in human neonates. We studied 172 preterm neonatal infants from two medical centers, the University of British Columbia and the University of California, San Francisco, by performing serial magnetic resonance imaging examinations near birth and again near term-equivalent age. After we adjusted for associated clinical factors, antenatal betamethasone was not associated with changes in cerebellar volume. Postnatal exposure to clinically routine doses of hydrocortisone or dexamethasone was associated with impaired cerebellar, but not cerebral, growth. Alterations in treatment after preterm birth, particularly glucocorticoid exposure, may help to decrease risk for adverse neurological outcome after preterm birth.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22013125 PMCID: PMC3682111 DOI: 10.1126/scitranslmed.3002884
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956